Subscribe
Rheumatology Practice Management February 2017 Vol 5 No 1 - ICER News
Rebecca Bailey

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report evaluating the clinical effectiveness and relative value—including value-based price benchmarks—of 11 rheumatoid arthritis therapies.1 All interested parties were given the opportunity to submit formal comments regarding the report and the draft voting questions to ICER by February 17, 2017. A version of the Draft Evidence Report with accompanying voting questions that includes any changes made based on feedback received during the public comment period will be posted to the ICER website on or around March 10, 2017, along with all of the comments that were submitted.

On March 24, 2017, this report will be the topic of a free, public meeting held by the New England Comparative Effectiveness Public Advisory Council, a nationally recognized community forum and core program of ICER, in Boston, MA. During this meeting, recommendations that can be translated to policy and practice in the field of rheumatology will be deliberated by an expert policy roundtable, and the New England Comparative Effectiveness Public Advisory Council will vote on important questions brought up in the Draft Evidence Report. There will also be a limited time frame allotted at this public meeting for attendees to make oral comments in response to the report. Clinicians, payers, and patients who wish to attend the meeting or watch it live via webcast can register at www.eventbrite.com/e/new-england-cepac-meeting-treatments-for-rheumatoid-arthritis-tickets-31259846041.

Reference

  1. Institute for Clinical and Economic Review. ICER releases draft evidence report on treatments for rheumatoid arthritis. January 20, 2017. https://icer-review.org/announcements/ra-draft-report/. Accessed February 14, 2017.
Related Items
ACR Responds to 2019 Benefit and Payment Parameters Proposed Rule
Rebecca Bailey
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in Health Policy
Final Report by Institute for Clinical and Economic Review Raises Concerns in the Rheumatology Community
Rebecca Bailey
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in Health Policy
How to Prepare for MACRA
Rebecca Bailey
Rheumatology Practice Management December 2016 Vol 4 No 6 published on December 28, 2016 in Conference News
Challenges and Opportunities in the Era of Biosimilar Therapy
Rebecca Bailey
Rheumatology Practice Management December 2016 Vol 4 No 6 published on December 28, 2016 in Conference News
Last modified: March 29, 2017
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search